



**Supplementary Fig. 3.** Changes in key efficacy parameters over time in the maintenance study. <sup>a</sup>Patients indicated in the legend are those randomized at week 0. UST, ustekinumab; F-CP, fecal calprotectin; CRP, C-reactive protein.